A systematic review of clinical guidelines on the management of acute, community-acquired CNS infections.
AGREE II appraisal
CNS infections
Encephalitis
Guidelines
Meningitis
Meningoencephalitis
Journal
BMC medicine
ISSN: 1741-7015
Titre abrégé: BMC Med
Pays: England
ID NLM: 101190723
Informations de publication
Date de publication:
06 09 2019
06 09 2019
Historique:
received:
21
02
2019
accepted:
09
07
2019
entrez:
7
9
2019
pubmed:
7
9
2019
medline:
7
1
2020
Statut:
epublish
Résumé
The epidemiology of CNS infections in Europe is dynamic, requiring that clinicians have access to up-to-date clinical management guidelines (CMGs) to aid identification of emerging infections and for improving quality and a degree of standardisation in diagnostic and clinical management practices. This paper presents a systematic review of CMGs for community-acquired CNS infections in Europe. A systematic review. Databases were searched from October 2004 to January 2019, supplemented by an electronic survey distributed to 115 clinicians in 33 European countries through the CLIN-Net clinical network of the COMBACTE-Net Innovative Medicines Initiative. Two reviewers screened records for inclusion, extracted data and assessed the quality using the AGREE II tool. Twenty-six CMGs were identified, 14 addressing bacterial, ten viral and two both bacterial and viral CNS infections. Ten CMGs were rated high quality, 12 medium and four low. Variations were identified in the definition of clinical case definitions, risk groups, recommendations for differential diagnostics and antimicrobial therapy, particularly for paediatric and elderly populations. We identified variations in the quality and recommendations of CMGs for community-acquired CNS infections in use across Europe. A harmonised European "framework-CMG" with adaptation to local epidemiology and risks may improve access to up-to-date CMGs and the early identification and management of (re-)emerging CNS infections with epidemic potential.
Sections du résumé
BACKGROUND
The epidemiology of CNS infections in Europe is dynamic, requiring that clinicians have access to up-to-date clinical management guidelines (CMGs) to aid identification of emerging infections and for improving quality and a degree of standardisation in diagnostic and clinical management practices. This paper presents a systematic review of CMGs for community-acquired CNS infections in Europe.
METHODS
A systematic review. Databases were searched from October 2004 to January 2019, supplemented by an electronic survey distributed to 115 clinicians in 33 European countries through the CLIN-Net clinical network of the COMBACTE-Net Innovative Medicines Initiative. Two reviewers screened records for inclusion, extracted data and assessed the quality using the AGREE II tool.
RESULTS
Twenty-six CMGs were identified, 14 addressing bacterial, ten viral and two both bacterial and viral CNS infections. Ten CMGs were rated high quality, 12 medium and four low. Variations were identified in the definition of clinical case definitions, risk groups, recommendations for differential diagnostics and antimicrobial therapy, particularly for paediatric and elderly populations.
CONCLUSION
We identified variations in the quality and recommendations of CMGs for community-acquired CNS infections in use across Europe. A harmonised European "framework-CMG" with adaptation to local epidemiology and risks may improve access to up-to-date CMGs and the early identification and management of (re-)emerging CNS infections with epidemic potential.
Identifiants
pubmed: 31488138
doi: 10.1186/s12916-019-1387-5
pii: 10.1186/s12916-019-1387-5
pmc: PMC6729038
doi:
Substances chimiques
Anti-Bacterial Agents
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
170Subventions
Organisme : Medical Research Council
ID : MR/T001151/1
Pays : United Kingdom
Références
Eur J Neurol. 2010 Aug;17(8):999-e57
pubmed: 20236175
BMJ. 2001 Jul 21;323(7305):155-7
pubmed: 11463690
Med Mal Infect. 2017 May;47(3):179-194
pubmed: 28412044
Clin Infect Dis. 2003 Mar 15;36(6):731-42
pubmed: 12627357
Emerg Infect Dis. 2005 Nov;11(11):1657-63
pubmed: 16318715
Med Mal Infect. 2017 May;47(3):221-235
pubmed: 28341533
Clin Infect Dis. 2013 Oct;57(8):1114-28
pubmed: 23861361
J Infect. 2012 Apr;64(4):347-73
pubmed: 22120595
Clin Microbiol Infect. 2017 Sep;23(9):601-606
pubmed: 28478238
Clin Microbiol Infect. 2018 Mar;24(3):229-239
pubmed: 28648861
Patholog Res Int. 2011;2011:878263
pubmed: 22315702
Eur J Neurol. 2008 Jul;15(7):649-59
pubmed: 18582342
Lancet. 2012 Nov 10;380(9854):1703-11
pubmed: 23141619
J Infect. 2012 May;64(5):449-77
pubmed: 22120594
Lancet Infect Dis. 2018 Sep;18(9):930-931
pubmed: 30153931
J Clin Epidemiol. 2010 Dec;63(12):1308-11
pubmed: 20656455
Clin Perinatol. 2015 Mar;42(1):29-45, vii-viii
pubmed: 25677995
J Infect. 2017 Jan;74(1):1-9
pubmed: 27746160
JAMA. 2001 Sep 26;286(12):1461-7
pubmed: 11572738
Lancet Infect Dis. 2018 Sep;18(9):992-1003
pubmed: 30153934
Clin Microbiol Infect. 2017 Sep;23(9):607-613
pubmed: 28501667
Clin Microbiol Infect. 2016 May;22 Suppl 3:S37-62
pubmed: 27062097
J Infect. 2016 Apr;72(4):405-38
pubmed: 26845731
Clin Infect Dis. 2008 Aug 1;47(3):303-27
pubmed: 18582201
Lancet Infect Dis. 2010 Dec;10(12):835-44
pubmed: 20952256
J Clin Epidemiol. 2012 May;65(5):526-34
pubmed: 22189163